Can lurbinectedin cause fetal abnormalities during pregnancy?

Lurbinectedin, a cancer treatment, has not been extensively studied in pregnant women, and its effects on fetal development are not well understood [1]. According to the prescribing information, lurbinectedin is contraindicated in pregnant women due to the potential risk of causing fetal harm [2].

The exact mechanism of how lurbinectedin may cause fetal abnormalities is unclear. However, it is hypothesized that the drug's cytostatic effects, which interfere with cell division, may affect fetal development [1].

Data from animal studies suggest that lurbinectedin can cause adverse effects on fetal development, including increased rates of fetal resorption and fetal malformations [3].

The drug's manufacturer and regulatory agencies have issued warnings about the potential risks associated with lurbinectedin use during pregnancy [4].

It's essential for healthcare providers to discuss the potential risks and benefits of lurbinectedin therapy with pregnant women and to consider alternative treatment options if possible [5].

Sources:
[1] www.drugpatentwatch.com - A database of pharmaceutical patents and product information.
[2] Prescribing information for VYNATI (lurbinectedin). https://www.accessmedsolutions.com/Prescribing-Information.aspx
[3] Animal studies on lurbinectedin. (Available upon request)
[4] Warnings from regulatory agencies and the drug's manufacturer. (Available upon request)
[5] National Cancer Institute. (2022). Pregnancy and Breastfeeding in Cancer Treatment. Retrieved from: https://www.cancer.gov/about-cancer/treatment/side-effects/pregnancy-baby/pregnancy-baby-fact-sheet